Overview

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2017-12-05
Target enrollment:
Participant gender:
Summary
This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).
Phase:
Phase 1
Details
Lead Sponsor:
Asana BioSciences